Silverback Therapeutics Inc

$13.60
(as of Jun 6, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Silverback Therapeutics Inc

Stock Price
$13.60
Ticker Symbol
SPRY
Exchange
NASDAQ

Industry Information for Silverback Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Silverback Therapeutics Inc

Country
USA
Full Time Employees
155

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

Fundamentals for Silverback Therapeutics Inc

Market Capitalization
$1,420,123,776
EBITDA
$-3,004,000
Dividends per Share
P/E Ratio
180.75
Forward P/E Ratio
0
Earnings per Share
$0.08
Earnings per Share Estimate Next Year
Profit Margin
8.97%
Shares Outstanding
98,210,496
Percent Owned by Insiders
22.95%
Percent Owned by Institutions
75.25%
52-Week High
52-Week Low

Technical Indicators for Silverback Therapeutics Inc

50-Day Moving Average
200-Day Moving Average
RSI
44.28
0.82

Analyst Ratings for Silverback Therapeutics Inc

Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About Silverback Therapeutics Inc

May 27, 2025, 8:00 AM EST
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc.  See more.
May 27, 2025, 8:00 AM EST
ARS Pharmaceuticals, Inc. See more.
May 22, 2025, 7:37 AM EST
Over the last 7 days, the United States market has dropped 1.1%, yet it remains up by 9.1% over the past year with earnings forecasted to grow by 14% annually. See more.
May 15, 2025, 8:04 AM EST
One thing we could say about the analysts on ARS Pharmaceuticals, Inc. See more.